Biocon saw the highest growth of 1.32% in patent filings and 1.99% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 1.32% and grants by 1.99%. GlobalData’s DataBook provides a comprehensive analysis of Biocon‘s patent filings and grants. Buy the databook here.
Biocon has been focused on protecting inventions in United States(US) with seven publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 30% filings and 40% grants. The United States(US), South Korea(KR), Australia(AU), and European Patent Office(EPO) patent Office are among the top ten patent offices where Biocon is filings its patents. Among the top granted patent authorities, Biocon has 40% of its grants in United States(US) and 20% in European Patent Office(EPO).
Roche and Johnson & Johnson could be the strongest competitors for Biocon
Patents related to climate change and rare diseases lead Biocon's portfolio
Biocon has the highest number of patents in climate change followed by, rare diseases. For climate change, nearly 50% of patents were filed and no patents were granted in Q2 2024.
Multiple sclerosis related patents lead Biocon portfolio followed by rheumatoid arthritis, and drug delivery devices
Biocon has highest number of patents in multiple sclerosis followed by rheumatoid arthritis, drug delivery devices, lupus erythematosus, and systemic lupus erythematosus.
For comprehensive analysis of Biocon's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.